Medpace (NASDAQ:MEDP) Upgraded at StockNews.com

Medpace (NASDAQ:MEDP) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday.

A number of other analysts have also weighed in on MEDP. Robert W. Baird upped their target price on shares of Medpace from $312.00 to $408.00 and gave the stock an “outperform” rating in a report on Wednesday, February 14th. UBS Group raised shares of Medpace from a “neutral” rating to a “buy” rating and upped their target price for the stock from $282.00 to $452.00 in a report on Thursday, February 15th. Jefferies Financial Group raised shares of Medpace from a “hold” rating to a “buy” rating and upped their target price for the stock from $340.00 to $450.00 in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on shares of Medpace in a report on Monday, March 18th. They set a “hold” rating and a $395.00 target price on the stock. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $395.60.

Medpace Trading Up 8.2 %

Shares of NASDAQ MEDP traded up $30.89 during midday trading on Tuesday, hitting $407.15. The company’s stock had a trading volume of 808,112 shares, compared to its average volume of 249,150. The stock has a fifty day moving average price of $397.68 and a 200 day moving average price of $323.14. Medpace has a one year low of $187.03 and a one year high of $419.42. The firm has a market capitalization of $12.61 billion, a price-to-earnings ratio of 45.85, a P/E/G ratio of 1.97 and a beta of 1.38.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, April 22nd. The company reported $3.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.45 by $0.75. Medpace had a net margin of 15.00% and a return on equity of 63.98%. The company had revenue of $511.00 million for the quarter, compared to analyst estimates of $512.39 million. During the same quarter in the previous year, the firm posted $2.27 earnings per share. The company’s quarterly revenue was up 17.7% compared to the same quarter last year. On average, equities research analysts predict that Medpace will post 10.53 earnings per share for the current fiscal year.

Insider Activity

In other Medpace news, VP Susan E. Burwig sold 102 shares of the stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total transaction of $41,106.00. Following the completion of the sale, the vice president now owns 15,181 shares of the company’s stock, valued at approximately $6,117,943. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other Medpace news, VP Susan E. Burwig sold 102 shares of the company’s stock in a transaction on Friday, March 15th. The shares were sold at an average price of $403.00, for a total value of $41,106.00. Following the completion of the transaction, the vice president now directly owns 15,181 shares in the company, valued at approximately $6,117,943. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Medpace Investors, Llc sold 13,988 shares of the company’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $386.39, for a total transaction of $5,404,823.32. Following the completion of the transaction, the insider now owns 5,525,959 shares of the company’s stock, valued at $2,135,175,298.01. The disclosure for this sale can be found here. In the last 90 days, insiders sold 189,340 shares of company stock valued at $76,651,647. Corporate insiders own 20.30% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Wellington Management Group LLP increased its stake in Medpace by 312.6% during the 3rd quarter. Wellington Management Group LLP now owns 421,313 shares of the company’s stock valued at $102,013,000 after purchasing an additional 319,210 shares in the last quarter. TD Asset Management Inc increased its stake in Medpace by 195.2% during the 4th quarter. TD Asset Management Inc now owns 467,041 shares of the company’s stock valued at $143,162,000 after purchasing an additional 308,816 shares in the last quarter. Invesco Ltd. increased its stake in Medpace by 67.6% during the 3rd quarter. Invesco Ltd. now owns 611,900 shares of the company’s stock valued at $148,159,000 after purchasing an additional 246,775 shares in the last quarter. Norges Bank bought a new stake in Medpace during the 4th quarter valued at about $59,163,000. Finally, Epoch Investment Partners Inc. increased its stake in Medpace by 82.3% during the 4th quarter. Epoch Investment Partners Inc. now owns 352,463 shares of the company’s stock valued at $108,040,000 after purchasing an additional 159,144 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.